# Phase II/III Study of Anti-VEGF in Neovascular AMD

> **NCT00021736** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eyetech Pharmaceuticals** · enrollment: 540 (—)

## Conditions studied

- Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** EYE001 anti-VEGF aptamer

## Key facts

- **NCT ID:** NCT00021736
- **Lead sponsor:** Eyetech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** —
- **Final completion:** 2002-07
- **Target enrollment:** 540 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021736, "Phase II/III Study of Anti-VEGF in Neovascular AMD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00021736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*